$12.54+0.29 (+2.37%)
P3 Health Partners Inc., a patient-centered and physician-led population health management company, provides superior care services in the United States.
P3 Health Partners Inc. in the Healthcare sector is trading at $13.15 with a market capitalization of $2.5B. Wall Street consensus targets $14.00 (2 analysts), implying a +6.5% move over the next 12 months. The stock is currently 22% below its 52-week high of $16.89, remaining 132.7% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $386.39M↑ | $384.81M↑ | $345.25M↓ | $355.79M↓ | $373.23M |
| Gross Profit | — | — | — | — | — |
| Operating Income | $8.24M↑ | -$153.87M↓ | -$44.22M↓ | -$34.12M↑ | -$38.09M |
| Net Income | $1.22M↑ | -$75.52M↓ | -$31.59M↓ | -$20.36M↑ | -$20.48M |
P3 Health Partners Inc., a patient-centered and physician-led population health management company, provides superior care services in the United States. It operates clinics and wellness centers. The company was founded in 2020 and is based in Hender...
President Trump’s 12-word remark, “I don’t think about Americans’ financial situation, I don’t think about anybody,” hit the wires, and the reaction showed up in the forgotten corners of the market, where micro-cap turnarounds priced like option contracts ripped higher on May 15 as traders rotated into beaten-down names with operational catalysts already in motion. ... Trump Rattled Markets Again and These 3 Forgotten Stocks Under $30 Were the Unlikely Winners
P3 Health Partners' (PIII) shares soared 182% amid heavy trading after the company posted overnight
Moby summary of P3 Health Partners Inc.'s Q1 2026 earnings call
P3 Health Partners Inc (PIII) reports robust Q1 performance, raises full-year outlook, and enhances balance sheet through strategic debt conversion.
The recent move to a reduced US$12.50 price target for P3 Health Partners, alongside an unchanged fair value estimate of US$10.25, signals a recalibration of expectations rather than a rewrite of the core story. Bullish analysts see the updated target as a reset on timing after weaker Q3 aEBITDA, while still pointing to underlying operational progress that they believe is not fully showing up in the numbers yet. As you read on, keep an eye on how these differing views shape the evolving...